Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 4Genitourinary 3Other solid neoplasm 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1Classical hematology 1

Conditions

Carcinoma, Hepatocellular 2Ovarian Neoplasms 1Melanoma 1Malignant Solid Tumour 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 141Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Ramucirumab 33Trastuzumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × ARQ 197 × Gastrointestinal × Clear all
NCT01075048 2021-04-08

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Daiichi Sankyo

Phase 1/2 Completed
131 enrolled 15 charts
Gastrointestinal

Colorectal Neoplasms

NCT01755767 2021-04-06

METIV-HCC

Daiichi Sankyo

Phase 3 Completed
383 enrolled 17 charts
Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT01178411 2021-03-10

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Completed
60 enrolled 11 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT01611857 2016-11-23

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

SCRI Development Innovations, LLC

Phase 1/2 Completed
49 enrolled 12 charts
GastrointestinalOther solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡